Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Bayer HealthCare Initiates Multinational PIII Trial for Hemophilia A Treatment BAY94-9027
July 12, 2012
- Nippon Chemiphar Aiming to Boost Generic Drug Sales to 30 Billion Yen in FY2014: President Yamaguchi
July 12, 2012
- Shionogi Files Lawsuit against InterMune of US over Royalties Payment
July 12, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Halaven Fails to Meet Primary Endpoints vs Capecitabine in PIII Study: Eisai
July 11, 2012
- Suzuken to Offer Voluntary Early Retirement Program for Record 500 Employees
July 11, 2012
- BMKK Applies for Orencia SC Injection
July 11, 2012
- Takeda to Offer US Dollar Senior Notes for Repaying Debt for Nycomed Acquisition
July 11, 2012
- Taisho HD Acquires Mexican Pharmaceutical Companies to Enter OTC Drug Business
July 11, 2012
- Shionogi Launches First European Development Base
July 10, 2012
- Otsuka Licenses Digital Health Technology from Proteus of the US
July 10, 2012
- Astellas Launches RLS Treatment Regnite on July 10
July 10, 2012
- Pharmaceutical Companies Set Up Private Power Generators in Preparation for Planned Power Outages
July 9, 2012
- Ethical Drug Sales Up 9.7% in May, Pushed by 2 Extra Working Days: Crecon Report
July 9, 2012
- MTPC Launches Argatroban for HIT Type II in the UK
July 9, 2012
- Bayer Confident in Pipeline, Regards Japan as Strategically Important Country: Mr Fibig
July 6, 2012
- Takeda Completes Acquisition of Multilab, Mid-Sized Brazilian Pharm Company
July 5, 2012
- Zonegran Approved for Monotherapy in Europe: Eisai
July 5, 2012
- Nippon Kayaku Considers Promotional Measures for Biosimilars, Vascular Embolization Medical Devices
July 5, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…